Liver stiffness diminishes with antiviral response in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 6, 2011, Pages 656-663

  Hezode C ^a,b   Castera L ^c   Roudot Thoraval, F ^a,b   Bouvier Alias, M ^b,d   Rosa, I ^e   Roulot, D ^f   Leroy, V ^g   Mallat, A ^a,b   Pawlotsky, J M ^b,d  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^f UNIVERSITÉ PARIS 13   (France)

^g UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; DIGESTIVE TRACT PARAMETERS; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

EID: 80052027568     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04765.x     Document Type: Article

References (42)

1. Thomas DL, Seeff LB,. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-98. (Pubitemid 40968202)
2. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
3. Fried MW, Shiffman ML, Reddy KR, et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al., Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
5. Manns MP, McHutchison JG, Gordon SC, et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65. (Pubitemid 32913521)
6. Bedossa P, DargÃre D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57. (Pubitemid 37466971)
7. Maharaj B, Maharaj RJ, Leary WP, et al., Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; i: 523-5. (Pubitemid 16138427)
8. Regev A, Berho M, Jeffers LJ, et al., Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
9. Rousselet MC, Michalak S, Dupre F, et al., Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64. (Pubitemid 40165369)
10. Castera L, Negre I, Samii K, Buffet C,. Pain experienced during percutaneous liver biopsy. Hepatology 1999; 30: 1529-30.
11. Cadranel JF, Rufat P, Degos F,. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 2000; 32: 477-81.
12. Castera L, Negre I, Samii K, Buffet C,. Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: a randomized placebo-controlled trial. Am J Gastroenterol 2001; 96: 1553-7. (Pubitemid 32455089)
13. Bravo AA, Sheth SG, Chopra S,. Liver biopsy. N Engl J Med 2001; 344: 495-500. (Pubitemid 32164902)
14. Sandrin L, Fourquet B, Hasquenoph JM, et al., Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13. (Pubitemid 38091720)
15. Pinzani M, Vizzutti F, Arena U, Marra F,. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 95-106. (Pubitemid 351234279)
16. Castera L,. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009; 16: 300-14.
17. Castera L, Pinzani M,. Non-invasive assessment of liver fibrosis: are we ready? Lancet 2010; 375: 1419-20.
18. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
19. Ziol M, Handra-Luca A, Kettaneh A, et al., Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54. (Pubitemid 40066382)
20. Castera L, Vergniol J, Foucher J, et al., Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50. (Pubitemid 40439195)
21. Friedrich-Rust M, Ong MF, Martens S, et al., Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
22. Castera L, Le Bail B, Roudot-Thoraval F, et al., Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 2009; 50: 59-68.
23. Castera L, Foucher J, Bernard PH, et al., Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35.
24. Chevaliez S, Bouvier-Alias M, Pawlotsky JM,. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol 2009; 47: 1726-32.
25. Marcellin P, Boyer N, Gervais A, et al., Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.
26. Shiratori Y, Imazeki F, Moriyama M, et al., Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24. (Pubitemid 30171890)
27. Poynard T, McHutchison J, Manns M, et al., Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13. (Pubitemid 34465173)
28. Camma C, Di Bona D, Schepis F, et al., Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42. (Pubitemid 38222174)
29. Everson GT, Balart L, Lee SS, et al., Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008; 27: 542-51. (Pubitemid 351316789)
30. Fraquelli M, Rigamonti C, Casazza G, et al., Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73. (Pubitemid 46999083)
31. Boursier J, Konate A, Gorea G, et al., Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol 2008; 6: 1263-9.
32. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J,. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-34.
33. Vergniol J, Foucher J, Castera L, et al., Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16: 132-40.
34. Coco B, Oliveri F, Maina AM, et al., Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-9. (Pubitemid 46587854)
35. Arena U, Vizzutti F, Corti G, et al., Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-4. (Pubitemid 351280705)
36. Oliveri F, Coco B, Ciccorossi P, et al., Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008; 14: 6154-62.
37. Vizzutti F, Arena U, Romanelli RG, et al., Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45: 1290-7. (Pubitemid 46775793)
38. Bruno S, Crosignani A, Facciotto C, et al., Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.
39. Bruno S, Stroffolini T, Colombo M, et al., Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87. (Pubitemid 46453759)
40. Mallet V, Gilgenkrantz H, Serpaggi J, et al., Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
41. Veldt BJ, Heathcote EJ, Wedemeyer H, et al., Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84. (Pubitemid 351664462)
42. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. (Pubitemid 43112690)